Home › NDC Lookup › RxCUI directory › RxCUI 2587070

1 ML ropeginterferon alfa-2b-njft 0.5 MG/ML Prefilled Syringe [Besremi] — RxCUI 2587070

RxNorm drug concept · Semantic branded drug
RxCUI 2587070 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2587070
Official name1 ML ropeginterferon alfa-2b-njft 0.5 MG/ML Prefilled Syringe [Besremi]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asBesremi 500 MCG per 1 ML Prefilled Syringe; BESREMi 500 MCG in 1 ML Prefilled Syringe
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)618 prescriptions · 11 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Ropeginterferon alfa-2b: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • BESREMi treats two blood disorders: polycythemia vera, where your bone marrow makes too many red blood cells, and essential thrombocythemia, where it makes too many platelets. Both...
  • What exactly is BESREMi being used to treat — is it a type of cancer?
  • BESREMi is given as an injection under the skin (subcutaneous injection) every two weeks, and the BESREMi Pen option makes it possible to self-inject at home once you've been train...
  • How do I take this medication — do I have to go to a clinic every time?
📖 Read our full Ropeginterferon alfa-2b guide →

🕸️ Concept Web — How 1 ML ropeginterferon alfa-2b-njft 0.5 MG/ML Pref... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 1 ML ropeginterferon alfa-2b-njft 0.5 MG/ML Prefilled Syringe [Besremi] RxCUI 2587070

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Ropeginterferon alfa-2b 2587059
    • Ropeginterferon alfa-2b-njft 2587060
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Besremi 2587066
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Ropeginterferon alfa-2b Prefilled Syringe 2587063
    • Ropeginterferon alfa-2b-njft Prefilled Syringe 2648028
    • Ropeginterferon alfa-2b Injectable Product 2587062
    • Ropeginterferon alfa-2b-njft Injectable Product 2659818
    • Ropeginterferon alfa-2b Prefilled Syringe [Besremi] 2587069
    • Ropeginterferon alfa-2b-njft Prefilled Syringe [Besremi] 2658592
    • Besremi Injectable Product 2587068
    • Prefilled Syringe 721656
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • 1 ML ropeginterferon alfa-2b-njft 0.5 MG/ML Prefilled Syringe SCD · 2587064
  • Ropeginterferon alfa-2b-njft 0.5 MG/ML SCDC · 2587061
  • Ropeginterferon alfa-2b Prefilled Syringe SCDF · 2587063
  • Ropeginterferon alfa-2b-njft Prefilled Syringe SCDFP · 2648028
  • Ropeginterferon alfa-2b Injectable Product SCDG · 2587062
  • Ropeginterferon alfa-2b-njft Injectable Product SCDGP · 2659818

Brand-Name Concepts

  • Ropeginterferon alfa-2b-njft 0.5 MG/ML [Besremi] SBDC · 2587067
  • Ropeginterferon alfa-2b Prefilled Syringe [Besremi] SBDF · 2587069
  • Ropeginterferon alfa-2b-njft Prefilled Syringe [Besremi] SBDFP · 2658592
  • Besremi Injectable Product SBDG · 2587068
  • Besremi BN · 2587066

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2587070 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
73536-0500-01 1 SYRINGE, GLASS in 1 CARTON (73536-500-01) / 1 mL in 1 SYR... BESREMi PharmaEssentia USA 2021-11-12
Observed labelers: PharmaEssentia USA (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.